TAIHO ONCOLOGY Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • TAIHO ONCOLOGY's estimated annual revenue is currently $91.1M per year.(i)
  • TAIHO ONCOLOGY's estimated revenue per employee is $201,000

Employee Data

  • TAIHO ONCOLOGY has 453 Employees.(i)
  • TAIHO ONCOLOGY grew their employee count by 22% last year.

TAIHO ONCOLOGY's People

NameTitleEmail/Phone
1
Senior Director, Quality AssuranceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is TAIHO ONCOLOGY?

Taiho Oncology, Inc. works urgently to discover and develop innovative cancer treatments. As cancer evolves, we evolve with itbringing novel technology to cornerstone chemotherapies, while at the same time optimizing new targeted agents. Advanced technology, dedicated investigators, and incomparable facilitiesthese vast resources empower us to redefine the way the world treats cancer. It's our work; it's our passion; it's our legacy.

keywords:N/A

N/A

Total Funding

453

Number of Employees

$91.1M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TAIHO ONCOLOGY News

2022-04-19 - Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

Previously, Mr. Zergebel served as Vice President, Project Management at Taiho Oncology where he was responsible for global project management...

2022-03-30 - US Food and Drug Administration (FDA) Accepts for Priority ...

Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in...

2022-03-30 - Taiho Pharmaceutical Obtains Approval to Manufacture and ...

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$191.2M4592%N/A
#2
$84.5M46623%N/A
#3
$169.8M5037%N/A
#4
$103M51510%N/A
#5
$300M5167%N/A